Tardy mar­ket­ing ap­pli­ca­tion fil­ing, tri­al fail­ure trou­ble Su­per­nus in­vestors

Two key up­dates sur­faced in CNS-fo­cused Su­per­nus Phar­ma­ceu­ti­cals third-quar­ter re­sults on Tues­day.

The drug­mak­er has not yet filed a mar­ket­ing ap­pli­ca­tion for its AD­HD drug SPN-812 — and a late-stage study test­ing an­oth­er ther­a­py, SPN-810, for use in im­pul­sive ag­gres­sion (IA) in pa­tients with AD­HD, has failed.

Shares of the Rockville, Mary­land-based com­pa­ny $SUPN — which al­so post­ed Q3 rev­enue and prof­it that un­der­whelmed Wall Street ex­pec­ta­tions — tum­bled more than 26% to $21.50 in Wednes­day pre­mar­ket trad­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER